Olympus banks on acquisitions to sustain its high
A strategic change towards Olympus's medical business, and particularly therapeutic procedures, has reignited growth. Next up: acquisitions.
A thoroughly average year for medtech mergers
Robotic surgery is one of the bright spots in an otherwise tricky year for medtechs seeking a buyer.
Big cap medtech comes roaring back
Exact Sciences finds that where there’s muck there’s brass, but specialisation does not work as well for Abiomed.
Thrive emerges with cash, a cancer blood test, and a plan
A new player has entered the liquid biopsy game.
Exact falls on Guardant’s liquid biopsy plans
The mere possibility of Guardant horning in on colorectal cancer has spooked Exact’s investors.
Check-Cap auditions for its screen debut
Check-Cap has a new spin on capsule endoscopy, using X-rays instead of a visual camera. But more compelling clinical data will be necessary if it is to position its…
Promotion deal is huge boost for Exact – but Pfizer must deliver
Pfizer is to push Exact’s cancer test in a deal that could “permanently alter the trajectory of Cologuard”.
Smaller medtechs soar in ’17 but could now be too expensive
Many small groups are up thanks to takeover speculation, and this may end up being self-defeating.
